Clover Health Investments Future Growth
Future criteria checks 3/6
Clover Health Investments is forecast to grow earnings and revenue by 57% and 7.5% per annum respectively while EPS is expected to grow by 52.9% per annum.
Key information
57.0%
Earnings growth rate
52.9%
EPS growth rate
| Healthcare earnings growth | 20.8% |
| Revenue growth rate | 7.5% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 17 Dec 2024 |
Recent future growth updates
Recent updates
Recent Earnings Disappointment Could Be An Ideal Buying Opportunity For Clover Health
Dec 21Clover Health: Buy The Dip, Reap The Rewards
Nov 18Clover Health Investments, Corp. (NASDAQ:CLOV) Just Reported Third-Quarter Earnings And Analysts Are Lifting Their Estimates
Nov 08
Clover Health's Rally: The Payoff Of A Profitable Pivot
Nov 06There's Reason For Concern Over Clover Health Investments, Corp.'s (NASDAQ:CLOV) Massive 37% Price Jump
Oct 03Clover Health: Changing Business Model, Seeking Profitability
Oct 03Clover Health: A Profitable Future Ahead Fueled By AI And Star Rating Success
Aug 15Clover Health Investments, Corp. (NASDAQ:CLOV) Surges 32% Yet Its Low P/S Is No Reason For Excitement
Aug 14Here's Why We're Watching Clover Health Investments' (NASDAQ:CLOV) Cash Burn Situation
Aug 06Clover Health Investments, Corp.'s (NASDAQ:CLOV) Price Is Right But Growth Is Lacking After Shares Rocket 26%
Jun 12Clover Health Investments, Corp.'s (NASDAQ:CLOV) 26% Dip In Price Shows Sentiment Is Matching Revenues
Apr 20Clover Health Investments, Corp. (NASDAQ:CLOV) Analysts Are Reducing Their Forecasts For This Year
Mar 16Will Clover Health Investments (NASDAQ:CLOV) Spend Its Cash Wisely?
Mar 06Clover Health: Its Luck May Have Ran Out
Feb 26Here's Why We're Not Too Worried About Clover Health Investments' (NASDAQ:CLOV) Cash Burn Situation
Nov 21We're Hopeful That Clover Health Investments (NASDAQ:CLOV) Will Use Its Cash Wisely
Jul 07Chamath Palihapitiya-linked Clover Health Investments trading near all-time low
Oct 14Chamath Palihapitiya cuts stake in Clover Health to under 5%
Oct 04Rethinking My Clover Health Position
Sep 12Clover Paid The Price Of Its Alleged Lies; Time To Move On
Aug 17Clover Health Investments to name president Andrew Toy as CEO
Aug 08Clover Health Is A Buy Ahead Of Earnings
Jul 29Clover Health to expand Medicare Advantage plans to 13 additional counties, exit 2
Jul 15Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 1,877 | -30 | -55 | N/A | 4 |
| 12/31/2025 | 1,589 | -60 | -76 | N/A | 4 |
| 12/31/2024 | 1,381 | -57 | -63 | N/A | 4 |
| 9/30/2024 | 2,115 | -96 | -110 | -109 | N/A |
| 6/30/2024 | 2,090 | -121 | -178 | -177 | N/A |
| 3/31/2024 | 2,059 | -157 | -170 | -169 | N/A |
| 12/31/2023 | 2,036 | -213 | -116 | -116 | N/A |
| 9/30/2023 | 1,864 | -226 | -183 | -178 | N/A |
| 6/30/2023 | 2,441 | -268 | -63 | -58 | N/A |
| 3/31/2023 | 2,989 | -344 | -155 | -150 | N/A |
| 12/31/2022 | 3,579 | -340 | -291 | -286 | N/A |
| 9/30/2022 | 3,041 | -443 | -76 | -75 | N/A |
| 6/30/2022 | 2,564 | -402 | -222 | -222 | N/A |
| 3/31/2022 | 2,075 | -615 | -247 | -246 | N/A |
| 12/31/2021 | 1,361 | -588 | -283 | -282 | N/A |
| 9/30/2021 | 1,158 | -527 | -263 | -262 | N/A |
| 6/30/2021 | 922 | -487 | -252 | -252 | N/A |
| 3/31/2021 | 721 | -160 | -175 | -174 | N/A |
| 12/31/2020 | 690 | -136 | -119 | -118 | N/A |
| 9/30/2020 | 624 | -89 | -126 | -126 | N/A |
| 6/30/2020 | 572 | -145 | -116 | -116 | N/A |
| 3/31/2020 | 507 | -272 | -163 | -163 | N/A |
| 12/31/2019 | 455 | -364 | -160 | -160 | N/A |
| 12/31/2018 | 281 | -202 | -155 | -153 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CLOV is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.6%).
Earnings vs Market: CLOV is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: CLOV is expected to become profitable in the next 3 years.
Revenue vs Market: CLOV's revenue (7.5% per year) is forecast to grow slower than the US market (9.2% per year).
High Growth Revenue: CLOV's revenue (7.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CLOV's Return on Equity is forecast to be high in 3 years time
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/27 06:55 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Clover Health Investments, Corp. is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kevin Fischbeck | BofA Global Research |
| Richard Close | Canaccord Genuity |
| Jason Cassorla | Citigroup Inc |